People
Boehringer Ingelheim’s Animal Health USA division will reimburse $379,089 in back pay and interest to 75 female employees to resolve alleged wage discrimination at its St. Joseph, Missouri, facility.
The trial remains on clinical hold and continues to indefinitely delay the company’s plans to seek regulatory approval for the treatment.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
The U.S. FDA placed a hold on the Emergency Use Authorization for convalescent plasma as a potential treatment for COVID-19 over what was described as a lack of robust data supporting its use.
Point-of-care testing is a critical tool in the battle against COVID-19, and researchers in Indiana are working around the clock to deliver rapid tests with high specificity.
In its filing, Sorrento did not provide a reason for Shao’s termination.
Shortly before COVID-19 patients’ conditions advance from moderate to severe, their levels of type I interferon (IFN) are present in the bloodstream drop.
“Joining the board will allow me to help guide and influence the development of a product from bench to bedside,” Franchimont told BioSpace. “I look forward to contributing to ongoing discussions on translation from bench science to the clinic, and ultimately to making real differences in the lives of patients.”
In the midst of an international pandemic, three high-profile public health officials are leaving government service.
DBV Technologies aims to fill the peanut allergy treatment gap, especially for highly allergic children, with their low dose epicutaneous immunotherapy (EPIT) patch Viaskin™ Peanut.
PRESS RELEASES